0
From the Archives Journals |

Prevention of Osteoporosis Associated With Chronic Glucocorticoid Therapy

Michael P. Heffernan, MD; Kenneth G. Saag, MD, MSc; June K. Robinson, MD; Jeffrey P. Callen, MD
JAMA. 2006;295(11):1300-1303. doi:10.1001/jama.295.11.1300.
Text Size: A A A
Published online

Extract

Sulzberger MB, Witten VH, Yaffe SN.Cortisone acetate administered orally in dermatologic therapy. Arch Dermatol Syphilol. 1951;64573-578
Link to Article[[XSLOpenURL/10.1001/archderm.1951.01570110043006]]
Michel BA, Bloch DA, Wolfe F, Fries J.Fractures in rheumatoid arthritis. J Rheumatol. 1993;201666-1669
PubMed
Ray NF, Chan JK, Thamer M, Melton LJ III.Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995. J Bone Miner Res. 1997;1224-35
PubMed
Chrischilles EA, Butler CD, Davis CS, Wallace RB.A model of lifetime osteoporosis impact [published correction appears in Arch Intern Med. 1922;152:655]. Arch Intern Med. 1991;1512026-2032
PubMed
Center JR, Nguyen TV, Schneider D, Sambrook PM, Eisman JA.Mortality after all major types of osteoporotic fracture in men and women. Lancet. 1999;353878-882
PubMed
Hannan EL, Magazine J, Wan JJ.  et al. Mortality and locomotion 6 months after hospitalization for hip fracture. JAMA. 2001;2852736-2742
PubMed
Trombetti A, Herrmann F, Hoffmeyer P.  et al. Survial and potential years of life lost after hip fracture in men and aged-matched women. Osteoporos Int. 2002;13731-737
PubMed
Johnell O, Kanis JA, Oden A.  et al. Mortality after osteoporotic fractures. Osteoporos Int. 2004;1538-42
PubMed
Miller W.Survival and ambulation following a hip fracture. J Bone Joint Surg Am. 1978;60A930-934
Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993;94646-650
PubMed
Bonar SK, Teinetti ME, Speechley M, Cooney LM.Factors associated with short- and long-term skilled nursing facility placement among community-living hip fracture patients. J Am Geriatr Soc. 1990;381139-1144
PubMed
Van Staa T, Leufkens HGM, Abenhaim L, Zhang B, Cooper C.Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15993-1000
PubMed
Rehman Q, Lane NE.Effect of glucocorticoids on bone density. Med Pediatr Oncol. 2003;41212-216
PubMed
van Staa TP, Leufkens HG, Cooper C.The epidemiology of corticosteroid-induced osteoporosis. Osteoporos Int. 2002;13777-787
PubMed
Luengo M, Picado C, Del Rio L, Guanabens N, Montserrat SM, Setoain J.Vertebral fractures in steroid dependent asthma and involutional osteoporosis. Thorax. 1991;46803-806
PubMed
American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum. 1996;391791-1801
PubMed
Adachi JD, Olszynski WP, Hanley DA.  et al. Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum. 2000;29228-251
PubMed
Sambrook PN, Diamond T, Ferris L.  et al. Osteoporosis Australia; National Asthma Campaign. Corticosteroid induced osteoporosis. Aust Fam Physician. 2001;30793-796
PubMed
Adler RA, Hochberg MC.Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs. Arch Intern Med. 2003;1632619-2624
PubMed
Geusens PP, de Nijs RN, Lems WF.  et al. Prevention of glucocorticoid osteoporosis. Ann Rheum Dis. 2004;63324-325
PubMed
Lester RS, Sandra RK, Neil HS.The risks of systemic corticosteroid use. Dermatol Clin. 1998;16277-286
PubMed
da Silva JA, Jacobs JW, Kirwan JR.  et al. Low-dose glucocorticoid therapy in rheumatoid arthritis. Ann Rheum Dis. 2006;65285-293
PubMed
Summey BT, Yosipovich G.Glucocorticoid-induced bone loss in dermatologic patients: an update. Arch Dermatol. 2006;14282-90
PubMed
Saag KG, Emkey R, Schnitzer TJ.  et al. Glucocorticoid-Induced Osteoporosis Intervention Study Group. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med. 1998;339292-299
PubMed
Cohen S, Levy RM, Keller M.  et al. Risedronate therapy prevents corticosteroid-induced bone loss. Arthritis Rheum. 1999;422309-2318
PubMed
Lane NE, Sanchez S, Modin GW.  et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. J Clin Invest. 1998;1021627-1633
PubMed
Liu RH, Albrecht J, Werth VP.Cross-sectional study of bisphosphonate use in dermatology patients receiving long-term oral corticosteroid therapy. Arch Dermatol. 2006;14237-41
Lozsadi DA, Peters G, Sadik HY.  et al. Prevention of osteoporosis in glucocorticoid-treated neurology patients. Clin Neurol Neurosurg. 2006;108157-162
Walsh LJ, Wong CA, Pringle M, Tattersfield AE.Use of oral corticosteroids in the community and the prevention of secondary osteoporosis. BMJ. 1996;313344-346
PubMed
Ip M, Larn K.Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids. Chest. 1994;1051722-1727
PubMed
Solomon DH, Katz JN, La Tourette AM, Coblyn JS.Multifaceted intervention to improve rheumatologists' management of glucocorticoid-induced osteoporosis. Arthritis Rheum. 2004;51383-387
PubMed
Naunton M, Peterson GM, Jones G.  et al. Multifaceted educational program increases prescribing of preventive medication for corticosteroid induced osteoporosis. J Rheumatol. 2004;31550-556
PubMed
Kiefe CI, Allison JJ, Williams OD.  et al. Improving quality improvement using achievable benchmarks for physician feedback. JAMA. 2001;2852871-2879
PubMed
Edge JC, Outland JD, Dempsey JR, Callen JP.Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol. 2006;14265-69
PubMed
Hantash B, Fiorentino D.Liver enzyme abnormalities in patients with atopic dermatitis treated with mycophenolate mofetil. Arch Dermatol. 2006;142109-110
PubMed
Enk AH, Knop J.Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol. 1999;13554-56
PubMed
Mimouni D, Anhalt GJ, Cummins DL.  et al. Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil. Arch Dermatol. 2003;139739-742
PubMed
Bystryn JC, Steinman NM.The adjuvant therapy of pemphigus: an update. Arch Dermatol. 1996;132203-212
PubMed
Burruss JB, Farmer ER, Callen JP.Chlorambucil is an effective corticosteroid-sparing agent for recalcitrant pyoderma gangrenosum. J Am Acad Dermatol. 1996;35720-724
PubMed

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 5

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs